39 pharmaceutical companies in Vermont

What do you know about the pharmaceutical companies in Vermont? Today, we unravel the essentials you need to know.

More than 560 clinical trials of new medicines have been conducted by pharmaceutical companies in Vermont in collaboration with the state’s university medical school, clinical research centers, and hospitals (1999 to present).

365 of the more than 560 clinical trials target the six most debilitating chronic diseases in Vermont: asthma, cancer, diabetes, heart disease, mental illnesses, and stroke.

Overview

Vermont is dedicated to good health for people, the environment, and institutions, which include schools, colleges and universities, businesses, and cities and communities.

The active research activity of pharmaceutical companies in Vermont—from Chittenden County to White River Junction, from Brattleboro to Bennington—is one significant health care effort that does not receive the attention it deserves.

Vermont Biosciences Alliance includes many of these institutions. Working frequently in collaboration with the NIH and the majority of major pharmaceutical companies, the research efforts contribute to the development of life-saving drugs, devices, and treatments.

A drug or a medical device cannot be developed by a single researcher or institution. Capital, talent, drive, initiative, and teamwork are all required.

Facts about pharmaceutical companies in Vermont

Pharmaceutical companies in Vermont have targeted disease wisely—well over half of the medications clinically tested in the state have targeted the nation’s most debilitating chronic diseases, including cancer, diabetes, heart disease, stroke, and asthma.

Nearly half of those trials are still recruiting patients. These collaborations have occurred in Burlington with researchers from the University of Vermont and Fletcher Allen Health Care Medical Center.

Pharmaceutical companies in Vermont are currently conducting or have completed over 560 clinical trials of new medicines in collaboration with the state’s university medical school, clinical research centers, and hospitals (1999 to present).
365 of the more than 560 clinical trials target the six most debilitating chronic diseases in the United States: asthma, cancer, diabetes, heart disease, mental illnesses, and stroke.
Pharmaceutical companies have provided jobs, tax revenue, and research funding to Vermont.
According to a study conducted by BattelleTechnology Partnership Practice, the industry supported nearly 1,500 jobs in the state in 2011.
Wages and benefits for employees supported by the pharmaceutical sector resulted in approximately $11 million in federal taxation and $2 million in state and local taxes.
Pharmaceutical companies in Vermont contributed $267 million in economic activity to the state two years ago, including direct economic output, output from vendors and suppliers, and output generated by the purchasing power of its workforce.
Life sciences researchers, management executives, office and administrative support workers, production workers, engineers, architects, computer and math experts, and sales representatives are among the company employees in Vermont.
Pharmaceutical companies also supported the jobs of their vendors and suppliers, such as construction and information technology firms. Employees of pharmaceutical companies in Vermont also contribute to the success of local restaurants, daycare centers, and other community businesses.

Concerning Clinical Trials

Clinical trials are used in the development of new medicines to demonstrate therapeutic safety and effectiveness and to compile the evidence required for the Food and Drug Administration (FDA) to approve treatments.
Clinical trials for new drugs are conducted in three stages, accounting for an average of seven of the ten to fifteen years it takes to bring a new drug from development to patients.
Clinical trials for a specific drug or treatment entail thousands of volunteer patient participants and the collection of tens of thousands of pages of technical and scientific data.
Clinical trials account for 45 to 75 percent of the average $1.2 billion costs of developing a new cutting-edge biotechnology medicine.
The trials provide another potential therapeutic option for patients. Clinical tests may provide a new avenue of care for some chronic disease patients who are still looking for the best medicines for them.
Some trials are also carried out to compare existing treatments, while others are carried out to determine whether a drug is appropriate for a specific patient population, such as children.
Others are being conducted to find ways to make currently approved drugs more effective, easier to use, and with fewer side effects. An Institutional Review Board (IRB), an independent committee of physicians, statisticians, local community advocates, and others, must review and approve all clinical trials to ensure that they are conducted ethically and that patient rights are protected.
Clinical trial progress reports must be submitted to the FDA and IRB at least once a year.
All facilities that conduct or support biomedical research involving patients must follow federal regulations and have an IRB.

New Generation Medicines in the Works

Some of the drugs tested in Vermont are cutting-edge pharmaceutical drugs. Today, pharmaceutical companies in the United States are using biotechnology to develop hundreds of new medications and vaccines.

Vermont is one of the states conducting this research and development. Biotechnology is creating new ways to not only treat disease more effectively but also to predict and even prevent it.

Biotechnology medicines are created through biological processes that use living cells or organisms, as opposed to traditional chemical synthesis, which has been the mainstay of pharmaceutical development for decades. Novel treatments employ a variety of novel approaches to disease treatment.

A monoclonal antibody, for example, is a laboratory-created version of a naturally occurring immune system protein that binds to and neutralizes foreign invaders. Interferons are proteins that inhibit a cell’s ability to reproduce.

Meanwhile, antisense drugs are medications that disrupt the communication process that instructs a cell to produce an unwanted protein. Nanotechnology is also being used in biotechnology research to develop drug delivery systems, new treatments, and diagnostics.

These technologies are used in some of the medicines being tested in clinical trials at Vermont hospitals and research facilities.

In Colchester, for example, a monoclonal antibody for the treatment of idiopathic pulmonary fibrosis is being tested. A recombinant fusion protein was studied in Burlington to treat age-related macular degeneration.

A monoclonal antibody targeting lymphoma is in clinical trials at Mountainview Medical in Berlin and Fletcher Allen Health Care Medical Center in Burlington.

The medicines and vaccines being developed today are helping to push science forward, which could lead to more and better treatments for patients.

This innovation in Vermont, as in other states, is the result of a successful collaboration between pharmaceutical companies and local research institutions.

Pharmaceutical companies in Vermont

Here’s a list of some of the pharmaceutical companies in Vermont:

Agilent

Website: Click here

Address: 100 Tigan St, Winooski, VT 05404, United States

Phone: +1 802-655-4040

Aircare Medical

Address: 85 Industry Street Williamstown, VT 05679

Phone: (802) 433-1355

Airgas

Address: 65 Granite Street Barre, VT 05641

Phone: (802) 476-5901

Amramp Western MA & VT

Address: 76 Hartness Ave Suite 2 Springfield, VT 05156

Phone: (844) 726-7327

Apria Healthcare

Address: 37 Commerce Avenue South Burlington, VT 05403

Phone: (802) 865-7801

Website: Click here

Biomosaics

Address: BioMosaics Inc., 655 Spear St., Building C, Burlington, VT 05405

Email: [email protected]

Phone: +1 877 742-2066/(+1 802 656-5443)

Burlington Drug Co

Address: 91 Catamount Drive Milton, VT 05468

Phone: (802) 893-5105

Website: Click here

Catamount Research and Development Inc.

Address: 166 Industrial Park Rd Fairfax, VT, 05454-4452 United States

Phone: (802) 527-2364

Revenue: $312,756

Year Started: 2014

Incorporated: 2006

Ceres LLC

Address: 190 College St Burlington, VT, 05401-8305 United States

Phone: (833) 237-3767

Website: Click here

Revenue: $432,680

Year Started: 2017

Edge Pharma, LLC

Address: 450 Weaver St Ste 3 Winooski, VT, 05404-4401 United States

Phone: (802) 992-1178

Revenue: $5.36 million

Year Started: 2013

Elution Technologies, LLC

Address: 480 Hercules Dr. Colchester, VT, 05446-7917 United States

Phone: (802) 540-0296

Website: Click here

Revenue: $104,369

Year Started: 2012

EQUITAS Life Sciences, LLC

Website: Click here

Email: [email protected]

Address: 5 Oliver Wight Drive, Unit B Essex, Vermont 05452

Genoa Healthcare

Address: 181 Crawford Farm Rd Room 130, Newport, VT 05855, United States

Toll-Free Phone: (800) 519-1139

Fax: (253) 218-0336

Email: [email protected]

Green Mountain Pharmaceutical

Address: 30 Myers Ct South Burlington, VT 05403

Phone: (802) 860-3301

Website: Click here

Haematologic Technologies

Address: 57 River Road Unit 1021 Essex Junction, VT 05452 USA

Phone: +1 (802) 878-1777

Fax: +1 (802) 878-1776

Herbs Horsetail

Address: 134 Manley Rd Milton, VT, 05468-9076 United States

Phone: (802) 893-0521

Website: Click here

Revenue: $129,917

Year Started: 2012

Kaman Composite

Address: 25 Performance Drive Bennington, VT 05201

Phone: (802) 442-9964

Keene Medical Products

Address: 160 Benmont Ave Suite 26 Bennington, VT 05201

Phone: (802) 447-7468

Lincare

Address: 201 South St Ste D Bennington, VT 05201

Phone: (802) 440-8125

MBF Bioscience

Address: 185 Allen Brook Lane, Suite 101 Williston, VT 05495 USA

Phone: 1-802-288-9290

Fax: 1-802-288-9002

Email: [email protected]

Mellow Root Herbals

Address: 200 McNally Dr. Waterville, VT, 05492-9709 United States

Phone: (802) 318-5518

Revenue: $111,995

Year Started: 2018

Microstrain

Address: 459 Hurricane Ln Suite 102 Williston, VT 05495

Phone: (802) 862-6629

Mobilityworks

Address: 5a David Drive Essex Junction, VT 05452

Phone: (802) 222-0265

Mylan Inc

Address: 700 Industrial Park Road St. Albans, VT 05478

Phone: (724) 514-1800

New Chapter, Inc.

Address: 90 Technology Dr. Brattleboro, VT, 05301-9180 United States

Phone: (800) 543-7279

Revenue: $52.53 million

Year Started: 1986

Incorporated: 2005

Prolytix

Address: 57 River Road Unit 1021 Essex Junction, VT 05452 USA

Phone: +1 (802) 878-1777

Fax: +1 (802) 878-1776

RESTART

Address: 119 Honeysuckle Lane Williston, VT 05495

Phone: (315) 842-7100

Rite Aid Pharmacy

Address: 213 Main St, Ludlow, VT 05149, United States

Phone: +1 802-228-8477

Rogue Herbalist

Address: 2859 Gregg Hill Rd Waterbury Center, VT, 05677-8102 United States

Phone: (904) 327-4317

Revenue: $67,702

Year Started: 2018

Sensorium Inc

Address: 617 Dorset Street Charlotte, VT 05445

Phone: (802) 425-2161

Website: Click here

Smith Drug Company

Address: 91 Catamount Dr, Milton, VT 05468, United States

Phone: +1 (800) 338-8703

Fax: +1 (864) 591-0333

Sweet Fern Gardens, LLC

Address: Roxbury, VT, 05669 United States

Phone: (802) 728-4971

Revenue: $284,689

Year Started: 2018

The Pharmacy Inc.

Address: 205 North Street Bennington, VT 05201

Phone: (802) 442-5602

Unither Neurosciences Inc

Address: 82 Pearl Street Burlington, VT 05401

Phone: (802) 651-0147

Website: Click here

Vernal Biosciences

Address: 261 Mountain View Dr. Colchester, VT 05446

Phone: (512) 791-9680

Vermed Inc

Address: 9 Lovell Drive Bellows Falls, VT 05101

Phone: (802) 463-9976

Vermont Family Pharmacy Inc

Address: 1219 North Ave Suite 10 Burlington, VT 05408

Phone: (802) 658-9664

Yankee Medical

Address: 141 Fairfax Road St. Albans, VT 05478

Phone: (802) 527-1343

Zydus Noveltech Inc

Address: 1775 Williston Rd Suite 210 South Burlington, VT 05403

Phone: (802) 861-4111

Website: Click here

FAQs about the pharmaceutical companies in Vermont

How many clinical trials have been sponsored by pharmaceutical companies in Vermont?

In Vermont alone, biopharmaceutical research companies have sponsored 365 clinical trials of potential new medicines for asthma, cancer, heart disease, stroke, diabetes, and mental illnesses since 1999. 48 of these trials are either not yet recruiting or are only now looking for Vermont patients. The 48 trials are taking place at 49 different locations throughout Vermont.

What is the employment rate in Vermont’s pharmaceutical sector?

According to a study conducted by BattelleTechnology Partnership Practice, the industry supported nearly 1,500 jobs in the state in 2011.

Wages and benefits for employees supported by the pharmaceutical sector resulted in approximately $11 million in federal taxation and $2 million in state and local taxes.

What are the top pharmaceutical companies in Vermont?

Top pharmaceutical firms

Inc. Mylan
Agilent Technologies, Inc.
Scientific Eurofins
Perrigo
AstraZeneca
Merck

What is the economic impact of pharmaceutical companies in Vermont?

Pharmaceutical companies in Vermont contributed $267 million in economic activity to the state two years ago, including direct economic output, output from vendors and suppliers, and output generated by the purchasing power of its workforce.

Vermont will soon become the first state in the country to require pharmaceutical manufacturers to explain the reasons for price increases.

Conclusion

The close collaboration of pharmaceutical companies with clinicians and research institutions in Vermont benefits patients, the state’s economy, and the advancement of science and patient care. Clinical trials stimulate pharmaceutical research and provide a consistent source of revenue for state medical schools, hospitals, and contract research organizations.

Furthermore, the drugs being tested are sometimes cutting-edge cell and protein treatments that have the potential to be safer and more effective than older chemical compound drugs.

Furthermore, Vermonters interested in participating in clinical trials have a variety of options, including 48 trials of new medicines for the six most debilitating chronic diseases.